These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35347645)

  • 1. AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
    Gumusgoz E; Kasiri S; Guisso DR; Wu J; Dear M; Verhalen B; Minassian BA
    Neurotherapeutics; 2022 Apr; 19(3):982-993. PubMed ID: 35347645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Gys1 with AAV-SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
    Gumusgoz E; Guisso DR; Kasiri S; Wu J; Dear M; Verhalen B; Nitschke S; Mitra S; Nitschke F; Minassian BA
    Neurotherapeutics; 2021 Apr; 18(2):1414-1425. PubMed ID: 33830476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GYS1 or PPP1R3C deficiency rescues murine adult polyglucosan body disease.
    Chown EE; Wang P; Zhao X; Crowder JJ; Strober JW; Sullivan MA; Xue Y; Bennett CS; Perri AM; Evers BM; Roach PJ; Depaoli-Roach AA; Akman HO; Pederson BA; Minassian BA
    Ann Clin Transl Neurol; 2020 Nov; 7(11):2186-2198. PubMed ID: 33034425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal Muscle Glycogen Chain Length Correlates with Insolubility in Mouse Models of Polyglucosan-Associated Neurodegenerative Diseases.
    Sullivan MA; Nitschke S; Skwara EP; Wang P; Zhao X; Pan XS; Chown EE; Wang T; Perri AM; Lee JPY; Vilaplana F; Minassian BA; Nitschke F
    Cell Rep; 2019 Apr; 27(5):1334-1344.e6. PubMed ID: 31042462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyglucosan body structure in Lafora disease.
    Brewer MK; Putaux JL; Rondon A; Uittenbogaard A; Sullivan MA; Gentry MS
    Carbohydr Polym; 2020 Jul; 240():116260. PubMed ID: 32475552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.
    Chambers JK; Thongtharb A; Shiga T; Azakami D; Saito M; Sato M; Morozumi M; Nakayama H; Uchida K
    Vet Pathol; 2018 Jul; 55(4):543-551. PubMed ID: 29444631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice.
    Nitschke S; Chown EE; Zhao X; Gabrielian S; Petković S; Guisso DR; Perri AM; Wang P; Ahonen S; Nitschke F; Minassian BA
    J Biol Chem; 2021; 296():100150. PubMed ID: 33277363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guaiacol as a drug candidate for treating adult polyglucosan body disease.
    Kakhlon O; Ferreira I; Solmesky LJ; Khazanov N; Lossos A; Alvarez R; Yetil D; Pampou S; Weil M; Senderowitz H; Escriba P; Yue WW; Akman HO
    JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease.
    Ahonen S; Nitschke S; Grossman TR; Kordasiewicz H; Wang P; Zhao X; Guisso DR; Kasiri S; Nitschke F; Minassian BA
    Brain; 2021 Nov; 144(10):2985-2993. PubMed ID: 33993268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyglucosan neurotoxicity caused by glycogen branching enzyme deficiency can be reversed by inhibition of glycogen synthase.
    Kakhlon O; Glickstein H; Feinstein N; Liu Y; Baba O; Terashima T; Akman HO; Dimauro S; Lossos A
    J Neurochem; 2013 Oct; 127(1):101-13. PubMed ID: 23607684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogen hyperphosphorylation underlies lafora body formation.
    Turnbull J; Wang P; Girard JM; Ruggieri A; Wang TJ; Draginov AG; Kameka AP; Pencea N; Zhao X; Ackerley CA; Minassian BA
    Ann Neurol; 2010 Dec; 68(6):925-33. PubMed ID: 21077101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
    Wang Y; Ma K; Wang P; Baba O; Zhang H; Parent JM; Zheng P; Liu Y; Minassian BA; Liu Y
    Mol Neurobiol; 2013 Aug; 48(1):49-61. PubMed ID: 23546741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease.
    Valles-Ortega J; Duran J; Garcia-Rocha M; Bosch C; Saez I; Pujadas L; Serafin A; Cañas X; Soriano E; Delgado-García JM; Gruart A; Guinovart JJ
    EMBO Mol Med; 2011 Nov; 3(11):667-81. PubMed ID: 21882344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model.
    Donohue KJ; Fitzsimmons B; Bruntz RC; Markussen KH; Young LEA; Clarke HA; Coburn PT; Griffith LE; Sanders W; Klier J; Burke SN; Maurer AP; Minassian BA; Sun RC; Kordasiewisz HB; Gentry MS
    Neurotherapeutics; 2023 Oct; 20(6):1808-1819. PubMed ID: 37700152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Astrocytes in the Pathophysiology of Lafora Disease and Other Glycogen Storage Disorders.
    Duran J
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease.
    Turnbull J; DePaoli-Roach AA; Zhao X; Cortez MA; Pencea N; Tiberia E; Piliguian M; Roach PJ; Wang P; Ackerley CA; Minassian BA
    PLoS Genet; 2011 Apr; 7(4):e1002037. PubMed ID: 21552327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laforin-malin complex degrades polyglucosan bodies in concert with glycogen debranching enzyme and brain isoform glycogen phosphorylase.
    Liu Y; Zeng L; Ma K; Baba O; Zheng P; Liu Y; Wang Y
    Mol Neurobiol; 2014 Apr; 49(2):645-57. PubMed ID: 24068615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myofiber-type-dependent 'boulder' or 'multitudinous pebble' formations across distinct amylopectinoses.
    Mitra S; Chen B; Shelton JM; Nitschke S; Wu J; Covington L; Dear M; Lynn T; Verma M; Nitschke F; Fuseya Y; Iwai K; Evers BM; Minassian BA
    Acta Neuropathol; 2024 Feb; 147(1):46. PubMed ID: 38411740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble Polyglucosan.
    Sullivan MA; Nitschke S; Steup M; Minassian BA; Nitschke F
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28800070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.